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Background: Biological agents for anti-tumor necrosis factor-α 
therapy have revolutionized treatments for autoimmune 
diseases; however, approximately 20% of rheumatology and 
40% of gastroenterology patients do not respond to the 
therapy, or they show reduced drug efficacy because of anti-
drug antibody (ADA) formation.
Objectives: To evaluate laboratory tools for individual moni- 
toring of infliximab therapy and the relationship between ADA 
and infliximab serum levels, ADA and clinical response, and 
ADA and autoantibodies.
Methods: Our study comprised patients treated with infliximab 
and affected by selected rheumatology and gastroenterology 
diseases. Sera were analyzed for infliximab, total-anti-drug 
antibodies (Total-ADA), and free-anti-drug antibodies (Free-ADA) 
serum levels and for the detection of specific autoantibodies.
Results: We analyzed 73 patients. Total-ADA were detected 
in 26 rheumatology and 21 gastroenterology patients. Serum 
infliximab levels were significantly lower in Total-ADA positive 
patients (P = 0.01 for rheumatology group, P = 0.02 for 
gastroenterology group). A lack of response was observed in 
7 rheumatology and 15 gastroenterology samples. Total-ADA 
serum levels were statistically significantly higher in patients 
with treatment failure in both groups (P = 0.01 and P = 0.001, 
respectively). There was no significant association between the 
presence of Total-ADA and other autoantibodies. Free-ADA were 
detected in only 27 rheumatology patients. Results showed a 
significant correlation with clinical outcome (P = 0.006). 
Conclusions: The correlation with clinical response suggests 
that the presence of ADA could interfere with efficacy of 
therapy. The tests for monitoring therapy may be an important 
tool to assist clinicians in early detection and prevention of 
therapy failure.
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ABSTRACT:
KEY WORDS:
T umor necrosis factor-alpha (TNF-α) is a 17 kDa protein consisting of 157 amino acids. TNF-α is mainly produced 
by natural killer cells, T lymphocytes, and macrophages and is 
expressed in some other cells such as fibroblasts, tumor cells, 
and neurons [1]. Biological TNF-α is a pleiotropic cytokine 
and has a key role in host defense mechanisms and initiates 
the response to local injury. However, in excess, the presence of 
TNF-α can lead to inappropriate inflammation and consequent 
tissue damage [2]. Unregulated TNF-α can contribute to several 
pathological situations, including immune-mediated inflam-
matory diseases such as rheumatoid arthritis (RA), ankylosing 
spondylitis (SpA), psoriatic arthritis (PA), ulcerative colitis 
(UC), Crohn’s disease (CD), and psoriasis. Both animal and 
human studies concerning the role of TNF-α in autoimmune 
disorders led to the development of TNF-α blockage therapy [3].
Infliximab was the first TNF-α inhibitor to be released on 
the market and it is one of the most commonly prescribed 
therapies. It is an immunoglobulin G1 (IgG1) monoclonal 
antibody containing a chimeric protein of approximately 
25% murine sequences (variable region) and approximately 
75% human sequences (constant region) [4]. It presents high 
specificity, affinity, and avidity for TNF-α, and it is capable of 
neutralizing the biological activity of TNF by binding to the 
soluble and transmembrane forms of TNF, preventing it from 
binding to cellular receptors and inducing the lysis of cells that 
produce TNF [4]. Infliximab and other biological agents have 
revolutionized the treatment of chronic inflammatory disease, 
thereby improving patient outcomes [5].
Although TNF-α antagonists are for the most part well toler-
ated, their safety and efficacy can be compromised by the develop-
ment of immune response against anti-TNF-α with the produc-
tion of anti-drug antibodies (ADA). Neutralizing ADA directly 
interferes with the ability of TNF-α-inhibitors to block TNF-α 
signaling through specific TNF-receptors on target cells. ADA may 
be directed against idiotopes inside or outside the TNF-binding 
fragments of the anti-TNF-α immunoglobulin construct [6].
The presence of ADA and the development of immunogenic-
ity is associated with primary or secondary failure of anti-TNF-α 
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therapy and with significant adverse events, such as infection 
and in-site infusion reaction. The lack of clinical response in 
patients with ADA may be explained by immune complex for-
mation between TNF-α inhibitors and ADA, thus suppressing 
drug activity. This situation may be related to an increased drug 
clearance, which leads to lowering serum drug levels [5].
Due to the clinical and economic implications linked to 
therapy failure and adverse events, laboratory testing for moni-
toring TNF-α inhibitor therapy has recently been developed to 
prevent such complications. 
Our study was designed to evaluate laboratory tools for 
monitoring infliximab therapy in patients with specific auto-
immune diseases. 
We assessed infliximab serum levels and ADA to study the 
relationship between ADA and infliximab concentration, ADA 
and clinical response, and ADA and specific autoantibodies of 
patients with RA, SpA, PA, UC, and CD.
PATIENTS AND METHODS
STUDY DESIGN 
A multi-center study was designed to recruit patients from the 
gastroenterology department at the University of Parma, Italy 
and the rheumatology and gastroenterology departments at the 
University of Modena, Italy. All laboratory tests were performed 
at the diagnostic laboratory department as OCSAE, Azienda 
USL, Modena, Italy. 
Durning a 12 month period (April 2015–April 2016) two 
groups of patients were enrolled: patients with rheumatology 
diseases (RA, SpA, and PA) and patients with gastroenterology 
disorders (CD and UC). All patients were prescribed infliximab 
(alone or with immunosuppressors) both naïve and through a 
follow-up program.
Blood samples were collected prior to individual infliximab 
administration and serum aliquots were used to test ADA, 
infliximab levels, and autoantibodies according to each disease. 
With the clinicians, we grouped patients as either respond-
ers or non-responders to infliximab therapy to study the cor-
relation between the presence of ADA and clinical outcome.
LABORATORY ASSAYS
For infliximab monitoring therapy we detected three param-
eters: infliximab serum levels, total-anti-infliximab antibodies 
(Total-ADA), and free-anti-infliximab antibodies (Free-ADA). 
Total-ADA measure the presence of total anti-drug antibodies 
(free in the serum and bound with the drug); whereas, Free-
ADA detect the ADA free from the drug in the serum.
Anti-infliximab antibodies and infliximab serum levels were 
measured using an ELISA commercial kit (Immunodiagnostik 
AG, Benhseim, Germany), following the manufacturer’s instruc-
tions. The cut-off value of ADA was determined as twice the 
optical density of the negative control supplied by the manufac-
turer’s instructions. The cut-off value for the presence of anti-
infliximab antibodies was set at 10 AU/ml, while the therapeutic 
range of infliximab was between 3 and 7 μg/ml.
For all patients, ANA, anti-extractable nuclear antigens 
(ENA), and anti-double strand dsDNA antibodies were 
detected. In addition, anti-citrullinated protein antibodies 
(ACPA) were measured in patients with RA, SpA, and PA, 
while anti-Saccaromyces Cerevisae antibodies (ASCA IgA 
and ASCA IgG) and anti-neutrophil cytoplasmic antibodies 
(ANCA) were tested in patients with CD and UC.
ANA and ANCA were detected by indirect immunofluo-
rescence (Hep-2 cells for ANA and ethanol fixed human neu-
trophil cells for ANCA, respectively), and ENA, ACPA, and 
ASCA IgA and IgG were detected by immunoassay. dsDNA was 
tested first by immunoassay and then positivity was confirmed 
by indirect immunofluorescence (Crithidia luciliae).
Statistical analysis was conducted using the Mann–Whitney 
test to study the association between the presence of anti-inflix-
imab antibodies, infliximab serum levels, and clinical response. 
The Fisher’s exact test was used to evaluate the association 
between the presence of ADA and other autoantibodies in all 
diseases.
RESULTS
We enrolled a total of 73 patients (21 females, 52 males) with a 
mean age of 50.15 years ± 8.44.
We found that 36 rheumatology patients (42 samples, 5 
patients were tested several times throughout the study period) 
were affected with RA, SpA, and PA (6, 24, and 6 patients, 
respectively) while 37 gastroenterology patients were affected 
with CD and UC (25 and 12 patients, respectively). 
For therapy monitoring, we measured infliximab serum 
levels and the presence of Total-ADA for all samples. 
Total-ADA antibodies were detected in 26 rheumatology 
samples and 21 gastroenterology samples. Serum infliximab 
levels were significantly lower in ADA-positive patients with 
respect to ADA negativity in both rheumatology (mean 2.19 
± 1.95 μg/ml, P = 0.01) and gastroenterology samples (mean 
5.36 ± 8.78 μg/ml, P = 0.02). Data are dispalyed in Figure 1A 
and Figure 1B.
A lack of response was observed in 7 rheumatology (16.7%) 
and 15 gastroenterology (40.5%) samples. Total-ADA serum 
levels were significantly higher in treatment failure patients 
with respect to patient responders for both groups (mean 
37.52 ± 53.23 AU/ml, P = 0.001 in RA, SpA, and PA patients; 
mean 30.30 ± 45.90 AU/ml, P = 0.01 in CD and UC patients) 
as detailed in Figure 2A and Figure 2B. 
The association between infliximab serum levels and clinical 
outcome was not statistically significant (P = 0.09 and P = 0.14 
in the rheumatology and gastroenterology groups, respectively) 
as shown in Figure 3A and Figure 3B.
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Free-ADA was detected in 27 rheumatology patients only. 
Although no correlation between the presence of Free-ADA 
and infliximab serum levels was found (mean 2.33 ± 1.99 μg/ml, 
P = 0.10) [Figure 1C], our data show a significant association 
between the presence of Free-ADA and clinical outcome (mean 
37.91 ± 72.40 AU/ml, P = 0.006) [Figure 2C]. 
We studied the association between the presence of Total-
ADA and ANA and anti-dsDNA and anti-ENA for all patients. 
There was no significant association identified between the 
presence of ADA and other autoantibodies, with the exception 
of ANCA (P = 0.01), as shown in Table 1.
DISCUSSION
Different assays have been developed to measure ADA serum 
concentrations for laboratory testing. We selected the ELISA 
assay to detect infliximab serum levels and ADA because this 
method is simple and quick to perform. It offers the possibility 
of total automation on laboratory instruments as well as total 
traceability of results, thus reducing the possibility of errors. 
However, the limitations of this test, such as the possibility of 
interference with other drugs and the presence of false-positive 
results, remain [7].
The results from the current study confirm that there is an 
inverse correlation between anti-drug antibodies and inflix-
imab levels, as has been identified in other studies [8]. The early 
detection of ADA could therefore be useful in determining 
the etiology of low infliximab sub-therapeutic levels, possibly 
facilitating clinical decision making regarding other therapeu-
tic options for these patients considered non-responders [9]. 
As with previous findings [6,10], our results also demonstrate 
that the presence of ADA interferes with clinical outcome. A 
significant association between the presence of Total-ADA and 
Free-ADA and treatment failure was confirmed. These data can 
be applied both for rheumatology and gastroenterology patients 
[10]. These results could have important implications for the 
strategy of therapy and the early detection of high ADA levels, 
thereby preventing a lack of therapeutic response and eventual 
treatment failure. 
In the literature, there is an active discussion concerning the 
detection of ANA and other autoantibodies during biological 
therapy treatment, as opposed to disease activity [6]. In the cur-
rent study, no correlation between ADA and autoantibodies 
was identified, suggesting that these autoantibodies should be 
used in the follow-up program only in the presence of specific 
clinical signs.
Our study design is limited because only five different dis-
eases were tested on a relatively small population size. Patients 
undergoing infliximab therapy alone or in conjunction with 
immunosuppressors were tested together, rendering the groups 
heterogeneous. Further studies should separate these patient 
groups to include larger populations, stratified according to 
Figure 3. Association between infliximab serum levels and clinical response in  
[A] rheumatology group and [B] gastroenterology group
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Figure 2. Association between Total-ADA 
serum levels and clinical response in 
[A] the rheumatology group and [B] the 
gastroenterology group. [C] Association 
between Free-ADA serum levels and 
clinical response in 27 patients with 
rheumatoid arthritis, ankylosing 
spondylitis, and psoriatic arthritis
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Figure 1. Association between infliximab 
serum levels and Total-ADA in  
[A] the rheumatology group and in 
[B] the gastroenterology group. Three 
outlier samples were omitted.  
[C] Association between infliximab 
serum levels and the presence of  
Free-ADA in 27 rheumatology patients 
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response, treatment failure, or side effects. Data from labora-
tory tests can assist clinicians in their therapy selection, and 
the introduction of these tests should be considered for routine 
biological therapy monitoring of autoimmune diseases. 
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the assumption of infliximab alone and infliximab in conjunc-
tion with immunosuppressors, to confirm current findings 
suggesting that immunosuppressors increase patient response 
to infliximab therapy. We also suggest conducting studies 
dedicated to the change in therapy response over time, during 
therapy assumption. Moreover, the correlation between ADA 
and adverse events is needed.
CONCLUSIONS
In conclusion, our study shows that laboratory tests of ADA 
and infliximab serum levels for patients with rheumatology 
and gastroenterology diseases are useful for the monitoring and 
management of patients assuming anti-infliximab-a therapies. 
These tests can help clinicians understand the causes for loss of 
Table 1. Autoantibodies anti-infliximab antibodies in rheumatology 
and gastroenterology groups of patients 
Autoantibodies
Total 
autoantibodies 
(positive) ADA+ ADA-
P 
value
Rheumatology 
group
ANA positive 32 22 10 0.14
ENA positive 0 0 0 –
dsDNA positive 7 6 1 0.22
ACPA positive 6 5 1 0.38
Gastroenterology 
group
ANA positive 14 9 5 0.51
ENA positive 0 0 0 –
dsDNA positive 1 1 0 1
*ANCA positive 8 1 7 0.011
*ASCA IgA positive 12 7 5 0.72
*ASCA IgG positive 13 8 5 0.47
*ANCA, ASCA IgA and ASCA IgG were tested only in 28 patients in the 
gastroenterology group
ANCA = anti-neutrophil cytoplasmic antibodies, ASCA = anti-citrullinated 
protein antibodies, IgA = immunoglobulin A ,IgG = immunoglobulin G,  
ENA = anti-extractable nuclear antigens, ANA = anti-nuclear antibodies
Geographic atrophy is a blinding form of age-related macular 
degeneration characterized by retinal pigmented epithelium 
(RPE) death. the RPE also exhibits DICER1 deficiency, 
resultant accumulation of endogenous Alu-retroelement RNA, 
and NLRP3-inflammasome activation. How the inflammasome 
is activated in this untreatable disease is largely unknown. 
Kerur and co-authors demonstrated that RPE degeneration 
in human-cell-culture and mouse models is driven by a 
noncanonical-inflammasome pathway that activates caspase-4 
(caspase-11 in mice) and caspase-1, and requires cyclic GMP-AMP 
synthase (cGAS)-dependent interferon-β production and 
gasdermin D-dependent interleukin-18 secretion. Decreased 
DICER1 levels or Alu-RNA accumulation triggers cytosolic 
escape of mitochondrial DNA, which engages cGAS. Moreover, 
caspase-4, gasdermin D, interferon-β, and cGAS levels were 
elevated in the RPE in human eyes with geographic atrophy. 
Collectively, these data highlight an unexpected role of cGAS in 
responding to mobile-element transcripts, reveal cGAS-driven 
interferon signaling as a conduit for mitochondrial-damage-
induced inflammasome activation, expand the immune-sensing 
repertoire of cGAS and caspase-4 to noninfectious human 
disease, and identify new potential targets for treatment of a 
major cause of blindness.
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cGAS drives noncanonical-inflammasome activation in age-related macular degeneration
